Sunstone: Here is the biotech investment for the future
The biotech companies of the future should be streamlined and to a much larger extent target exit opportunities in Asia, believes Peter Benson of Sunstone Capital. The venture capital fund is ready with freshly-printed venture capital for the sector.
af LEONORA BECK
The venture capital fund Sunstone Capital is ready with new ‘risk-willing’ capital for the money-starved biotech companies. The companies should shape themselves according to the demands of investors, and consequently company-structures will look very different in the future, assesses Peter Benson – leading partner in the fund.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
